# A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

> **NCT00363636** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 340 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin's

## Interventions

- **DRUG:** Galiximab in combination with rituximab
- **DRUG:** Rituximab in combination with placebo

## Key facts

- **NCT ID:** NCT00363636
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-04
- **Target enrollment:** 340 (ACTUAL)
- **Why stopped:** Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363636, "A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00363636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*